Cadrenal Therapeutics, Inc. Common Stock
CVKD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $6 | $0 |
| Gross Profit | -$0 | $0 | -$6 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $688 | $1,077 | $1,668 | $1,538 |
| G&A Expenses | $2,045 | $2,656 | $2,255 | $2,740 |
| SG&A Expenses | $2,045 | $2,656 | $2,255 | $2,740 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,733 | $3,734 | $3,922 | $4,278 |
| Operating Income | -$2,734 | -$3,734 | -$3,928 | -$4,278 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $48 | $67 | $83 | $91 |
| Pre-Tax Income | -$2,686 | -$3,667 | -$3,845 | -$4,187 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,686 | -$3,667 | -$3,845 | -$4,187 |
| % Margin | – | – | – | – |
| EPS | -1.31 | -1.87 | -2.09 | -2.75 |
| % Growth | 29.9% | 10.5% | 24% | – |
| EPS Diluted | -1.31 | -1.87 | -2.09 | -2.75 |
| Weighted Avg Shares Out | 2,044 | 1,962 | 1,844 | 1,525 |
| Weighted Avg Shares Out Dil | 2,044 | 1,962 | 1,844 | 1,525 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48 | $67 | $83 | $91 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $6 | $0 |
| EBITDA | -$2,685 | -$3,734 | -$3,840 | -$4,187 |
| % Margin | – | – | – | – |